147 related articles for article (PubMed ID: 37743493)
1. Prognosis of Midkine and AT1R expression in resectable head and neck squamous cell carcinoma.
Chiu TJ; Chen CH; Chen YJ; Wee Y; Wang CS; Luo SD
Cancer Cell Int; 2023 Sep; 23(1):212. PubMed ID: 37743493
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
[TBL] [Abstract][Full Text] [Related]
3. [Expression of angiotensin II type 1 receptor in cervical squamous cell carcinoma and its clinical significance].
Liao YD; Xu H; Han Q; Lei J; Zhang YY; Wang ZH
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):360-4. PubMed ID: 17892132
[TBL] [Abstract][Full Text] [Related]
4. Midkine promotes glioblastoma progression via PI3K-Akt signaling.
Hu B; Qin C; Li L; Wei L; Mo X; Fan H; Lei Y; Wei F; Zou D
Cancer Cell Int; 2021 Sep; 21(1):509. PubMed ID: 34556138
[TBL] [Abstract][Full Text] [Related]
5. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor type 1 blockers suppress the cell proliferation effects of angiotensin II in breast cancer cells by inhibiting AT1R signaling.
Du N; Feng J; Hu LJ; Sun X; Sun HB; Zhao Y; Yang YP; Ren H
Oncol Rep; 2012 Jun; 27(6):1893-903. PubMed ID: 22426690
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II type I receptor (AT1R) is an independent prognosticator of esophageal squamous cell carcinoma and promotes cells proliferation via mTOR activation.
Li SH; Lu HI; Chang AY; Huang WT; Lin WC; Lee CC; Tien WY; Lan YC; Tsai HT; Chen CH
Oncotarget; 2016 Oct; 7(41):67150-67165. PubMed ID: 27564102
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma.
Lu J; Liu QH; Wang F; Tan JJ; Deng YQ; Peng XH; Liu X; Zhang B; Xu X; Li XP
J Exp Clin Cancer Res; 2018 Jul; 37(1):147. PubMed ID: 30001734
[TBL] [Abstract][Full Text] [Related]
9. Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy.
Gowhari Shabgah A; Ezzatifar F; Aravindhan S; Olegovna Zekiy A; Ahmadi M; Gheibihayat SM; Gholizadeh Navashenaq J
IUBMB Life; 2021 Apr; 73(4):659-669. PubMed ID: 33625758
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the growth factor MDK/midkine by a novel small molecule compound to treat non-small cell lung cancer.
Hao H; Maeda Y; Fukazawa T; Yamatsuji T; Takaoka M; Bao XH; Matsuoka J; Okui T; Shimo T; Takigawa N; Tomono Y; Nakajima M; Fink-Baldauf IM; Nelson S; Seibel W; Papoian R; Whitsett JA; Naomoto Y
PLoS One; 2013; 8(8):e71093. PubMed ID: 23976985
[TBL] [Abstract][Full Text] [Related]
11. Midkine promotes breast cancer cell proliferation and migration by upregulating NR3C1 expression and activating the NF-κB pathway.
Zhang L; Song L; Xu Y; Xu Y; Zheng M; Zhang P; Wang Q
Mol Biol Rep; 2022 Apr; 49(4):2953-2961. PubMed ID: 35028860
[TBL] [Abstract][Full Text] [Related]
12. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma.
St John MA
Laryngoscope; 2015 Mar; 125 Suppl 3():S1-11. PubMed ID: 25646683
[TBL] [Abstract][Full Text] [Related]
14. Silencing novel long non-coding RNA FKBP9P1 represses malignant progression and inhibits PI3K/AKT signaling of head and neck squamous cell carcinoma in vitro.
Yang YF; Feng L; Shi Q; Ma HZ; He SZ; Hou LZ; Wang R; Fang JG
Chin Med J (Engl); 2020 Sep; 133(17):2037-2043. PubMed ID: 32769488
[TBL] [Abstract][Full Text] [Related]
15. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.
Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J
Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981
[TBL] [Abstract][Full Text] [Related]
16. Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma.
Yamashita T; Shimada H; Tanaka S; Araki K; Tomifuji M; Mizokami D; Tanaka N; Kamide D; Miyagawa Y; Suzuki H; Tanaka Y; Shiotani A
Cancer Med; 2016 Mar; 5(3):415-25. PubMed ID: 26798989
[TBL] [Abstract][Full Text] [Related]
17. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.
Li B; Zhu J; Meng L
Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Midkine expression in patients with solid tumors: a systematic review and meta-analysis.
Zhang L; Song X; Shao Y; Wu C; Jiang J
Oncotarget; 2018 May; 9(37):24821-24829. PubMed ID: 29872508
[TBL] [Abstract][Full Text] [Related]
19. Prognostic potential of Akt, pAkt(Ser473) and pAkt(Thr308) immunoreactivity in relation to HPV prevalence in head and neck squamous cell carcinoma patients.
Janecka-Widła A; Majchrzyk K; Mucha-Małecka A; Słonina D; Biesaga B
Pathol Res Pract; 2022 Jan; 229():153684. PubMed ID: 34839095
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
